Close Menu

stock downgrade

Analyst William Quirk remained bullish on the firm but downgraded the shares based on their valuation, which he said have little room to grow.

Even as Hologic enters the "sweet spot" in the adoption cycle for its 3D tomography tests, Evercore said there is "limited upside" to the company's current share price.

The investment bank noted the potential of Alere's new MDx platforms, but said that Quest's potential could suffer in comparison to its competitor LabCorp.

The downgrade follows Roche's proposed bid to acquire a majority stake in the company.

The investment bank downgraded Meridian Bioscience from a prior Market Perform rating, noting challenges to its molecular diagnostics business. 

The investment bank expressed doubts about Qiagen's GeneReader NGS platform, among other things, and Bruker's mixed recent record on improving its operations.

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded Hologic's stock from Outperform to Market Perform and lowered its price target on the shares.

NEW YORK (GenomeWeb News) – Investment firm Mizuho today downgraded Waters, citing "choppiness around the pharmaceutical market" that may cause the company's stock to "languish."

NEW YORK (GenomeWeb News) – Investment firm ISI Group today downgraded shares of Cepheid to Sell, saying it expects the Sunnyvale, Calif. molecular diagnostics firm's base business to slow due to increased competition in the hospital-acquired infection space.

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has downgraded Illumina to Neutral from Overweight and also has cut its price target on the stock.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.